Compare Gemini Space Station Inc (GEMI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs TransMedics Group Inc — how do they compare? Gemini Space Station Inc trades at $4.05 (market cap $512.05M), while TransMedics Group Inc trades at $87.66 (market cap $3.10B). The key difference: TransMedics Group Inc is far larger — about 6.1× Gemini Space Station Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| GEMI | TMDX | |
|---|---|---|
Market Cap | $512.05M | $3.10B |
Sector | Technology | Technology |
52-Week High | $32.52 | $150.42 |
52-Week Low | $3.90 | $61.99 |
Enterprise Value | $502.04M | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GEMI trades at $4.04, down 1.7% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $582.81M in 2025 on revenue of $179.57M, with negative gross and net income margins. Recent news includes a $100M investment from Winklevoss Capital and multiple class-action lawsuits alleging securities law violations.
The outlook remains challenging due to persistent losses and legal overhangs, though analyst consensus suggests a potential upside to $6.33. Key risks include ongoing unprofitability, competitive pressures in financial services, and regulatory scrutiny. Investment opportunity hinges on the company's ability to achieve profitability and navigate legal challenges.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
